152 related articles for article (PubMed ID: 12676237)
1. A priori molecular descriptors in QSAR: a case of HIV-1 protease inhibitors. II. Molecular graphics and modeling.
Kiralj R; Ferreira MM
J Mol Graph Model; 2003 Jun; 21(6):499-515. PubMed ID: 12676237
[TBL] [Abstract][Full Text] [Related]
2. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
3. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
Santos-Filho OA; Hopfinger AJ
J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
[TBL] [Abstract][Full Text] [Related]
4. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
[TBL] [Abstract][Full Text] [Related]
5. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
Halder AK; Jha T
Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
[TBL] [Abstract][Full Text] [Related]
6. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
7. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
8. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis.
Nunthanavanit P; Anthony NG; Johnston BF; Mackay SP; Ungwitayatorn J
Arch Pharm (Weinheim); 2008 Jun; 341(6):357-64. PubMed ID: 18442018
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
[TBL] [Abstract][Full Text] [Related]
12. Refining the multiple protein structure pharmacophore method: consistency across three independent HIV-1 protease models.
Meagher KL; Lerner MG; Carlson HA
J Med Chem; 2006 Jun; 49(12):3478-84. PubMed ID: 16759090
[TBL] [Abstract][Full Text] [Related]
13. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
15. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
[TBL] [Abstract][Full Text] [Related]
16. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(4):1297-307. PubMed ID: 12870923
[TBL] [Abstract][Full Text] [Related]
17. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
18. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
Li D; Liu MS; Ji B; Hwang K; Huang Y
J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
[TBL] [Abstract][Full Text] [Related]
20. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]